Daewoong Pharmaceutical secured an exclusive license to Innovo Therapeutics’ INV-008 in a deal potentially valued at about ₩662.5 billion (US$443.6 million), the companies said. The licensed compound is an oral 15-hydroxyprostaglandin dehydrogenase inhibitor being developed for inflammatory bowel disease. The transaction adds to Daewoong’s rare disease and GI-focused pipeline options and gives Innovo a financing and development pathway tied to broader execution milestones. While specific trial timelines were not detailed in the excerpt, the size of consideration signals the asset’s perceived differentiation in its mechanism. For biotech investors, the key read-through is continued large-scale licensing of mechanism-driven IBD programs, often aimed at pairing oral convenience with pathway specificity. Both parties will be expected to align on further clinical development and regulatory planning for INV-008, with economics reflecting a long runway typical for IBD disease-modifying candidates.